Galapagos and Gilead commence Phase II trial of filgotinib for uveitis
Belgian biotechnology firm Galapagos and its collaboration partner Gilead Sciences has commenced a Phase II clinical trial of filgotinib to treat patients suffering from uveitis. (Source: Drug Development Technology)
Source: Drug Development Technology - July 5, 2017 Category: Pharmaceuticals Source Type: news
Ferring reports positive outcome from Phase III trials of fertility drug
Swiss biopharmaceutical company Ferring Pharmaceuticals has reported a positive outcome from the Phase III ESTHER-1 and ESTHER-2 clinical trials of its fertility drug, Rekovelle. (Source: Drug Development Technology)
Source: Drug Development Technology - July 5, 2017 Category: Pharmaceuticals Source Type: news
June ’s top stories: NIH’s Phase I/II trial for chikungunya, Boehringer & Eli Lilly ’s empagliflozin trial
A new Phase I/II clinical trial of MV-CHIKV for the prevention of the chikungunya virus began enrolment, while Boehringer Ingelheim, along with Eli Lilly and Company, made plans to evaluate empagliflozin in a new clinical outcomes trial for chronic k … (Source: Drug Development Technology)
Source: Drug Development Technology - July 4, 2017 Category: Pharmaceuticals Source Type: news
Boehringer reports positive safety profile of Jardiance for type 2 diabetes
Boehringer Ingelheim has reported a positive safety profile of oral Jardiance (empagliflozin) for the treatment of adults with type 2 diabetes. (Source: Drug Development Technology)
Source: Drug Development Technology - July 4, 2017 Category: Pharmaceuticals Source Type: news
BrainStorm chooses Worldwide as CRO for Phase III ALS trial
US-based biotechnology company BrainStorm Cell Therapeutics has chosen Worldwide Clinical Trials as the clinical research organisation (CRO) for its upcoming Phase III clinical trial of NurOwn for treatment of patients with amyotrophic lateral sclero … (Source: Drug Development Technology)
Source: Drug Development Technology - July 4, 2017 Category: Pharmaceuticals Source Type: news
Noxxon Pharma starts dosing in Phase I/II trial of NOX-A12 for cancer
German firm Noxxon Pharma has started dosing patients in a Phase I/II clinical trial of NOX-A12 (olaptesed pegol) in combination with Keytruda (pembrolizumab) to treat metastatic colorectal and pancreatic cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - July 4, 2017 Category: Pharmaceuticals Source Type: news
Bayer begins Phase III programme of vilaprisan to treat uterine fibroids
Bayer has started a Phase III ASTEROID clinical programme of vilaprisan with enrolment of the first patient for treatment of uterine fibroids. (Source: Drug Development Technology)
Source: Drug Development Technology - July 3, 2017 Category: Pharmaceuticals Source Type: news
Oxford University to investigate AZD1775 for bowel cancer
The UK's University of Oxford is set to investigate AstraZeneca ’s experimental drug AZD1775 in a new clinical trial for treatment of patients with bowel cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - July 3, 2017 Category: Pharmaceuticals Source Type: news
Zealand starts enrolment in Phase III trial of dasiglucagon for hypoglycemia
Denmark-based biotechnology firm Zealand Pharma has started patient enrolment in Phase III clinical trial of dasiglucagon to treat severe hypoglycaemia in diabetic patients. (Source: Drug Development Technology)
Source: Drug Development Technology - July 3, 2017 Category: Pharmaceuticals Source Type: news
Daiichi Sankyo reports top-line results from Phase III trials of mirogabalin
Japanese pharmaceutical firm Daiichi Sankyo has reported top-line results from its Phase III NEUCOURSE and ALDAY clinical trials of mirogabalin to treat post-herpetic neuralgia and fibromyalgia. (Source: Drug Development Technology)
Source: Drug Development Technology - July 2, 2017 Category: Pharmaceuticals Source Type: news
eTheRNA initiates Phase Ib trial of TriMix-MEL for metastatic melanoma
Belgium-based cancer therapies developer eTheRNA Immunotherapies has initiated a Phase Ib clinical trial of TriMix-MEL (ECI-006) to treat patients with metastatic melanoma. (Source: Drug Development Technology)
Source: Drug Development Technology - July 2, 2017 Category: Pharmaceuticals Source Type: news
Aerpio starts dosing in Phase IIb trial of diabetic retinopathy drug
US-based Aerpio Pharmaceuticals has started dosing patients in the Phase IIb (TIME-2b) clinical trial of its product candidate AKB-9778, which could be used to treat patients with non-proliferative diabetic retinopathy. (Source: Drug Development Technology)
Source: Drug Development Technology - July 2, 2017 Category: Pharmaceuticals Source Type: news
An Analysis of Polymer Branching Using GPC / SEC Methodology
Polymer branching has been proven to have a potentially considerable impact on many physical properties of synthesised polymers, such as the disruption of crystallinity and a possible increase in single chain density and chain entanglements. (Source: Drug Development Technology)
Source: Drug Development Technology - July 2, 2017 Category: Pharmaceuticals Source Type: news
NIAID-funded trial shows use of common antimicrobials for MRSA abscesses
A clinical trial funded by the National Institute of Allergy and Infectious Diseases' (NIAID) health division has demonstrated the use of common and inexpensive antimicrobials to heal skin abscesses caused by methicillin-resistant Staphylococcus aure … (Source: Drug Development Technology)
Source: Drug Development Technology - June 29, 2017 Category: Pharmaceuticals Source Type: news
Deals this week: Selecta Biosciences, bluebird bio, TransGenic
Selecta Biosciences intends to raise $50m through private placement of shares of its common stock to be subscribed to by new and existing institutional investors and one of the company ’s board of directors. (Source: Drug Development Technology)
Source: Drug Development Technology - June 29, 2017 Category: Pharmaceuticals Source Type: news
